文献速递前列腺癌膀胱癌与上尿路尿路上皮癌

局限性前列腺癌近距离放疗后继发性膀胱癌和直肠癌的长期发病率:一项大规模人群分析

Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis.
PubMed 文献 · BJU Int · 2019-06-24

基于SEER数据库(1988-2015)纳入318058例局限性前列腺癌患者,其中55566例(18.4%)接受近距离放疗。倾向评分匹配后,近距离放疗组20年继发性膀胱癌发生率为6.0%,根治性前列腺切除术组为2.4%(P<0.001);直肠癌发生率分别为1.1%和0.5%(P<0.001)。多变量竞争风险模型显示,近距离放疗预测更高的继发性膀胱癌(HR 1.58;P<0.001)和直肠癌发生率(HR 1.59;P<0.001)。

要点

  • 近距离放疗组20年继发性膀胱癌发生率为6.0%,根治性前列腺切除术组为2.4%(P<0.001)。
  • 近距离放疗组20年继发性直肠癌发生率为1.1%,根治性前列腺切除术组为0.5%(P<0.001)。
  • 多变量竞争风险模型显示,近距离放疗预测更高的继发性膀胱癌(HR 1.58;P<0.001)和直肠癌发生率(HR 1.59;P<0.001)。

核心结论

  • 近距离放疗主要增加继发性膀胱癌风险,对直肠癌风险增加程度较小。
  • 因此需要对这类患者进行随访。
  • 令人鼓舞的是,继发性膀胱癌和尤其是直肠癌的发生率近期均有所下降。

研究设计与样本

  • 基于监测、流行病学和最终结果(SEER)数据库(1988-2015)的大规模人群分析。
  • 纳入局限性前列腺癌作为唯一或第一原发癌并接受近距离放疗或根治性前列腺切除术的患者。
  • 共纳入318058例局限性前列腺癌患者,其中55566例(18.4%)接受近距离放疗。
  • 采用累积发生率图和 multivariable 竞争风险回归(CRR)模型进行分析。
  • 敏感性分析聚焦于患者年龄和诊断年份区间,并检验未测量混杂因素的影响。

主要发现

  • 倾向评分匹配后,近距离放疗组20年继发性膀胱癌发生率为6.0%,根治性前列腺切除术组为2.4%(P<0.001)。
  • 倾向评分匹配后,近距离放疗组20年继发性直肠癌发生率为1.1%,根治性前列腺切除术组为0.5%(P<0.001)。
  • 多变量竞争风险回归模型中,与根治性前列腺切除术相比,近距离放疗预测更高的继发性膀胱癌(HR 1.58;P<0.001)和直肠癌发生率(HR 1.59;P<0.001)。
  • 按年龄分层后敏感性分析重复了相同结果,且按历史、中期和当代诊断年份显示HRs幅度递减。
  • 若一个未测量混杂因素HR为2,且其影响根治性前列腺切除术组患者相对于近距离放疗组的比率为2,则可使近距离放疗的效应在统计学上不显著。

临床怎么用

  • 原文结论指出需要对接受近距离放疗的患者进行随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the incidence and time trends of secondary bladder cancer (BCa) and rectal cancer (RCa) after brachytherapy (BT) relative to radical prostatectomy (RP). MATERIALS AND METHODS: Within the Surveillance, Epidemiology and End Results (SEER) database (1988-2015), we identified patients with localized PCa as an only or first primary cancer, who underwent BT or RP. Cumulative incidence plots and multivariable competing-risks regression (CRR) models were used. Sensitivity analyses focused on patients' age and year of diagnosis intervals and tested the effect of an unmeasured confounder. RESULTS: Of 318 058 patients with localized prostate cancer (PCa), 55 566 (18.4%) underwent BT. After propensity score-matching, 20-year secondary BCa incidence was 6.0% in patients who had undergone BT vs 2.4% in those who had undergone RP (P < 0.001) and the respective 20-year secondary RCa incidence was 1.1% vs 0.5% (P < 0.001). In multivariable CRR models, BT predicted higher secondary BCa (hazard ratio [HR] 1.58; P < 0.001) and RCa rates (HR 1.59; P < 0.001) vs RP. Sensitivity analyses replicated the same results after stratification according to age and showed HRs of decreasing magnitude for historical, intermediate and contemporary years of diagnosis. An unmeasured confounder with an HR of 2 would render the effect of BT statistically insignificant if it affected patients in the RP group with a ratio of 2 relative to those in the BT group. Finally, temporal trends showed a decrease of secondary 5-year BCa and RCa rates.> CONCLUSIONS: Brachytherapy predominantly increases the risk of secondary BCa and, to a lesser extent, that of RCa. Follow-up of such patients is therefore required. It is encouraging that both secondary BCa, and RCa rates, in particular, have recently decreased, RCa.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Mazzone E, Mistretta FA, Knipper S, et al. Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis. BJU Int. 2019. PMID: 31144770. doi:10.1111/bju.14841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。